Vaccine against mumps containing a JERYL-LYNN virus strain

A mumps, mumps virus strain technology, applied in medical preparations containing active ingredients, viruses/phages, antibody medical ingredients, etc., can solve problems such as inability to ensure balance and difficulty in estimating proportions

Inactive Publication Date: 2006-04-26
GLAXOSMITHKLINE BIOLOGICALS SA
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, as the Jeryl-Lynn strain is further passaged, there is no guarantee that this balance between the two variants will be maintained
It is also difficult to estimate the proportion of these two variants in any batch of vaccines

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine against mumps containing a JERYL-LYNN virus strain

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0024] 1) Preliminary sequencing of the SH gene

[0025] at 25cm 2 On the overgrown monolayer Vero cells in the culture flask, use dMEM Biorich medium (50 / 50V / V) plus 0.5% fetal bovine serum to inoculate about 3.0log TCID 50MumpsVax virus was commercially available for passaging. Incubate at 34°C for 7 days, then harvest infected cells, extract RNA by the method of Ferré and Garduno (Nucleic Acids Research 1989, 17; 2141), place in 100mcl water, and treat with diethylpyrocarbonate at 100°C 5 minutes. Take 5 mcl of such extracts and add the following reagents for reverse transcription: 40 units of RNAsin (Boehringer Mannheim, Germany), 4 mcl of 5X concentrated reverse transcriptase buffer (Bethesda Besearch Labs), 2 mcl of a mixture of four deoxynucleoside triphosphates The concentration was 10 mM, 10 pmole NH2 oligonucleotide primer, 1 mcl Moloney murine leukemia virus (MMLV) reverse transcriptase (Bethesda Research Labs, 200 units per mcl), and water was added to make the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention proposes a novel mumps vaccine comprising a homogeneously purified isolate derived from the Jeryl-Lynn strain of mumps virus. The vaccine in the preferred embodiment of the invention produces higher seroconversion rates and antibody titers than known commercial vaccines.

Description

[0001] related application [0002] This application is a divisional application of Chinese patent application 94194807.2 submitted to China Patent Office on July 10, 1996. technical field [0003] The present invention relates to a mumps vaccine comprising a homogeneous purified isolate derived from the Jeryl-Lynn strain of mumps virus. Background technique [0004] Mumps is basically a disease of children, usually with mild clinical symptoms. However, the clinical consequences of mumps infection are severe in some cases. For example, mumps is the most common cause of meningoencephalitis in children under 15 years of age and a cause of permanent sensorineural deafness in children in the United Kingdom. Although 30-40% of natural mumps infections are asymptomatic, the salivary glands are involved and, in the adult population, mumps causes first trimester abortion in addition to the neurological complications mentioned above and orchitis, these are indisputable facts that ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N7/00A61KA61K39/165C12N
Inventor 奈杰尔·M·哈福德布里格特·D·A·科劳让·迪德莱兹
Owner GLAXOSMITHKLINE BIOLOGICALS SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products